Alfuzosin

Evidence Level: L5

Predicted Indications: 10

Alfuzosin

Pharmacist Assessment Report

Alfuzosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Alfuzosin is an alpha-1A-selective adrenergic antagonist originally used to treat benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Ambras type hypertrichosis universalis congenita, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on model output alone.

Quick Overview

Item	Content
Original Indication	Benign prostatic hyperplasia
Predicted New Indication	Ambras type hypertrichosis universalis congenita
TxGNN Prediction Score	1.0000
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, alfuzosin is an alpha-1A-selective adrenergic antagonist. Its efficacy in BPH is established, but a mechanistic link to the new indication is not.

Ambras syndrome is a rare congenital disorder linked to genomic rearrangements affecting TRPS1 regulation. An alpha-1 blocker is not expected to act on this genetic basis. The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

The other top predictions point the same way. They include hypertrichosis, several congenital hair and malformation syndromes, and hypotrichosis (the opposite phenotype). That contradiction suggests the scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence or pharmacology. Some vasoactive drugs, such as minoxidil, are known to cause hypertrichosis, so a vascular route to hair growth is conceivable. However, alfuzosin has no documented hair-growth effect.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 14183L	Xatral SR	Tablet 10 mg (oral)	Not stated in the data compiled for this report

Safety Considerations

Contraindications flagged in the knowledge graph (these are graph relationships, not label text): multiple system atrophy, postural orthostatic tachycardia syndrome, orthostatic hypotension, hypotensive disorder, long QT syndrome (including familial), torsades de pointes, liver failure, liver disease, gallbladder disease, and intraoperative floppy iris syndrome.
Drug Interactions: 100 interactions were identified (the first 20 were available for review).
- Major: cisapride, clarithromycin, dolasetron.
- Moderate: famotidine, aprepitant, bisacodyl, bupropion, SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), granisetron, levofloxacin, clotrimazole, dronabinol, and several laxatives (castor oil, glycerin, lactitol, lactulose).
- Minor: cimetidine.
- The QT-related items (cisapride, dolasetron, clarithromycin) are consistent with the long QT and torsades flags above.

Label warnings and contraindications were not available, so please refer to the TGA-approved Product Information (PI) for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has no supporting trials or publications (L5), and no plausible mechanism has been identified. The score appears to be a TxGNN model (deep learning) artefact. The hair-related predictions are also internally inconsistent, covering both excess hair growth and hair loss.

To proceed, the following is needed:

Mechanism of action data for alfuzosin, and a plausible biological link to TRPS1 or hair follicle biology
Preclinical evidence (for example, hair follicle or cell models) showing a relevant effect
Systematic literature and trial registry searches (including ANZCTR) to confirm there is no existing evidence
Review of the ARTG product information, including the approved indication, warnings and contraindications
A safety assessment for the target population, including hypotension and QT-related risks
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.